<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE MedlineCitationSet PUBLIC "-//NLM//DTD Medline Citation, 1st January, 2009//EN"
                                    "http://teamsite.nlm.nih.gov:81/iw-mount/default/main/nlm/STAGING/htdocs/databases/dtd/nlmmedline_090101.dtd">
<MedlineCitationSet>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID>17395669</PMID>
<DateCreated>
<Year>2007</Year>
<Month>08</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-201X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>93</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Heart (British Cardiac Society)</Title>
<ISOAbbreviation>Heart</ISOAbbreviation>
</Journal>
<ArticleTitle>B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans.</ArticleTitle>
<Pagination>
<MedlinePgn>1077-80</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>BACKGROUND: The association between B-type natriuretic peptide (BNP) and coronary artery disease is not fully understood. OBJECTIVE: To assess whether ischaemia per se is a stimulus for BNP secretion. SETTING: University tertiary hospital, Spain (Virgen de la Arrixaca). DESIGN: Prospective interventional study. PATIENTS: 11 patients (55 (9) years, left ventricular ejection fraction (LVEF) 45% (7%) with a non-complicated anterior myocardial infarction (MI) and isolated stenosis of the left anterior descending (LAD) coronary artery, successfully treated by primary angioplasty. INTERVENTIONS: 11.0 (0.9) days after MI, the LAD was occluded (20 min) for intracoronary infusion of progenitor cells. Blood samples were obtained from the femoral artery (peripheral circulation (PC)) and the coronary sinus (coronary circulation (CC)) immediately before and after coronary occlusion. MAIN OUTCOME MEASURES: BNP (pg/ml) was measured and ischaemia biomarkers were monitored. RESULTS: During coronary occlusion, all patients experienced transitory chest pain and ST-segment dynamic changes. After coronary occlusion, lactic acid levels rose in CC (1.42 (0.63) -1.78 (0.68) ng/ml, p = 0.003). Myoglobin and cardiac troponin T did not differ in CC or PC at 24 h. No differences were found in LVEF (+0.18% (2.4)%, p = 0.86) and motion score index (-0.02 (0.06), p = 0.37). Before occlusion, BNP levels did not differ significantly in CC versus PC (253 (56) vs 179 (34), p = 0.093). After occlusion, BNP showed a significant increase in CC (vs 332 (61), p = 0.004), but no change occurred in PC (vs 177 (23), p = 0.93), and circulating BNP levels were higher in CC versus PC (p = 0.008). CONCLUSIONS: In response to acute ischaemia, BNP levels immediately increase in coronary sinus but not at the peripheral level. BNP release in the coronary effluent may exert local beneficial effects.</AbstractText>
</Abstract>
<Affiliation>Department of Cardiology, University Hospital Virgen de la Arrixaca, University of Murcia, Murcia, Spain. dapascual@servicam.com</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pascual-Figal</LastName>
<ForeName>Domingo A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Antolinos</LastName>
<ForeName>María J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bayes-Genis</LastName>
<ForeName>Antoni</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Casas</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nicolas</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Valdés</LastName>
<ForeName>Mariano</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>03</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Heart</MedlineTA>
<NlmUniqueID>9602087</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>114471-18-0</RegistryNumber>
<NameOfSubstance>Natriuretic Peptide, Brain</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Acute Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coronary Circulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Ischemia</DescriptorName>
<QualifierName MajorTopicYN="Y">blood</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
<QualifierName MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stroke Volume</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID>17395670</PMID>
<DateCreated>
<Year>2007</Year>
<Month>08</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-201X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>93</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Heart (British Cardiac Society)</Title>
<ISOAbbreviation>Heart</ISOAbbreviation>
</Journal>
<ArticleTitle>Cigarette smoking induces atrial fibrosis in humans via nicotine.</ArticleTitle>
<Pagination>
<MedlinePgn>1056-63</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>BACKGROUND: Cigarette smoking (CS) promotes endothelial dysfunction and atherosclerosis in the vascular bed. The impact of smoking on atrial myocardium is not defined in humans. OBJECTIVE: To determine the effect of CS on the development of interstitial fibrosis in atrial myocardium. DESIGN: Case-control study. PATIENTS: 95 patients (46 smokers and 49 non-smokers) undergoing coronary artery bypass grafting (CABG). MAIN OUTCOME MEASURES: Amount of atrial fibrosis, collagen I, III and IV expression pattern, and quantitative reverse transcriptase-PCR. Occurrence of postoperative atrial fibrillation (AF). RESULTS: In the study population, patient age correlated significantly with the amount of atrial fibrosis (r = 0.18; p&lt;0.05). Nicotine misuse (pack years) was identified as the only factor related to atrial fibrosis in smokers (r = 0.311; p&lt;0.05). The amount of fibrosis was higher in patients with postoperative AF (22.9% (6.2%) vs. 27.0% (8.2%); p&lt;0.05). To show a causal relationship between CS and atrial fibrosis, atrial tissue slices from non-smokers (n = 8) were cultured in the presence of nicotine base (185 and 740 nmol/l). Nicotine base induced mRNA expression of collagen III (up to 10-fold) in a concentration-dependent manner resembling the immunohistological collagen expression pattern observed in CS. CONCLUSION: CS contributes to the development of atrial fibrosis via nicotine. Atrial fibrosis by itself has been shown to provide an arrhythmogenic substrate, which may increase the likelihood of the occurrence of atrial arrhythmias, including postoperative AF.</AbstractText>
</Abstract>
<Affiliation>Institute of Experimental Internal Medicine, Division of Cardiology, Department of Cardiovascular Surgery, University Hospital Magdeburg, Magdeburg, Germany. andreas.goette@medizin.uni-magdeburg.de</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Goette</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lendeckel</LastName>
<ForeName>Uwe</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuchenbecker</LastName>
<ForeName>Anja</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bukowska</LastName>
<ForeName>Alicja</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Peters</LastName>
<ForeName>Brigitte</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klein</LastName>
<ForeName>Helmut U</ForeName>
<Initials>HU</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huth</LastName>
<ForeName>Christof</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Röcken</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>03</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Heart</MedlineTA>
<NlmUniqueID>9602087</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>54-11-5</RegistryNumber>
<NameOfSubstance>Nicotine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance>Collagen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Atrial Fibrillation</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Collagen</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Coronary Artery Bypass</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibrosis</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Atria</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardium</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Nicotine</DescriptorName>
<QualifierName MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Postoperative Complications</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tissue Culture Techniques</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID>17483125</PMID>
<DateCreated>
<Year>2007</Year>
<Month>08</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2007</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-201X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>93</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2007</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Heart (British Cardiac Society)</Title>
<ISOAbbreviation>Heart</ISOAbbreviation>
</Journal>
<ArticleTitle>Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up.</ArticleTitle>
<Pagination>
<MedlinePgn>1104-10</MedlinePgn>
</Pagination>
<Affiliation>AstraZeneca R&amp;D Södertälje, Södertälje, Sweden. moller@pubcare.uu.se</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ström Möller</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zethelius</LastName>
<ForeName>Björn</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sundström</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lind</LastName>
<ForeName>Lars</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>05</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Heart</MedlineTA>
<NlmUniqueID>9602087</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>57-88-5</RegistryNumber>
<NameOfSubstance>Cholesterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
<QualifierName MajorTopicYN="Y">mortality</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Electrocardiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epidemiologic Methods</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocardial Infarction</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sweden</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
</MedlineCitationSet>
